ABSTRACT
The efficiency of Siemens E.CAM is evaluated by analyzing and practicing the technology of Siemens U-fly.Basic testing procedure is run.Standard source 99mTc and 57Co is used respectively and the operation is performed according to the instruction.The detecting head's uniformity can be corrected in this way with satisfactory results.It is suggested uniformity should be tested every day before study because it is the most important factor for the quality of clinical images.
ABSTRACT
<p><b>OBJECTIVE</b>A certain fraction of patients failed palliative treatment of 153Sm- ethylenediaminetetramethy lenephosphate (153Sm-EDTMP) for painful skeletal metastases were reviewd. A comparative analysis was designed to identify the factors related to therapeutic response.</p><p><b>METHODS</b>From a 3-year multi-center clinical trial, 51 cases were collected who did not respond to an intravenous injection of 153Sm-EDTMP at a dosage of 0.5-1.5 mCi/kg. The therapeutic efficacy was evaluated via changes of symptoms, general condition, consumption of analgesics, sum of effect product, and Karnofsky scores. The age, sex, history of treatment, tumor type, location of bony involvement, uptake ratio and number of metastases, and doses used by the patients were compared to those of the responders.</p><p><b>RESULTS</b>In 51 non-responders, 43 were male, 34 suffered from lung cancer, 41 had bone lesions in the vertebrae, 39 in the pelvis, and 24 had metastases in the lower extremities. Sex distribution, tumor type and location of the lesion differed significantly between responders and non-responders. No other factor showed differences between the two groups. Though patients of younger age, and lesions with lower uptake of radiopharmaceutical seemed to fail the treatment more easily as observed clinically, this was not confirmed by statistical analysis.</p><p><b>CONCLUSION</b>The sex of the patients, certain types of primary tumors and metastases to lower parts of the body were found to influence the patients' response to a single dose of 153Sm-EDTMP palliation. Further exploration of a better way to determine dosage and predict response for each individual case is needed.</p>
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Analgesics, Non-Narcotic , Therapeutic Uses , Bone Neoplasms , Radiotherapy , Logistic Models , Organometallic Compounds , Therapeutic Uses , Organophosphorus Compounds , Therapeutic Uses , Palliative CareABSTRACT
It is the first time to lay down a complete and accurate plan for clinical verification protocol of domestic SPECT. The protocol's application to the first domestic BHP6601 SPECT proves its definitive purpose, reliability and completion. The protocol can meet the requirements of the criterions of China and related department, and thus must be beneficial to the clinical verification and popularization of large-scale nuclear medicine image equipment.